A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

By F. Saad, D. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J. Chin, J. Vinholes, J. Goas, Bee Chen. Journal of the National Cancer Institute, 2002

1,745 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/6b58f2313ebb5ca024e8c6b1eb5e87de1e022fbd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016, methodology): “Reduction in the frequency of SREs is an approvable end point in its own right, used in several trials to support the approval of zoledronic acid and denosumab.(57,58) The registration study of radium-223 used a composite bone end point, symptomatic skeletal events (SSEs), defined as symptomatic fra”
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. (2011, background): “Denosumab has been studied in two phase II trials of patients with bone metastasis and advanced cancer and in one phase II trial with myeloma.26-28 These studies showed that treatment with denosumab at doses ranging from 30 to 180 mg administered every 4 or 12 weeks was associated with rapid and sus”
EAU guidelines on prostate cancer. (2001, background): “The use of zoledronate has demonstrated a clinically significant effect in terms of prevention of skeletal complications and reduction of pain, or even total pain relief, in patients with hormone-refractory PCa [51].”
Osteoblasts in prostate cancer metastasis to bone (2005, background): “Trials of one such agent, zoledronate, for patients with advanced prostate cancer showed that it reversed bone loss from hormonal therapy but did not slow cancer progressio”
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, methodology): “A total of 643 patients who had CRPC [161] with bone metastases were randomised to receive zoledronic acid, 4 or 8 mg every 3 wk for 15 consecutive months, or placebo.”